or Try an Advanced Search...

    Technical Analysis for MIRA - MIRA Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 1.27 -9.64% -0.14
    MIRA closed down 9.64 percent on Wednesday, November 20, 2024, on 59 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical MIRA trend table...
    Date Alert Name Type % Chg
    Fell Below 50 DMA Bearish 0.00%
    Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
    200 DMA Support Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -9.64%
    Narrow Range Bar Range Contraction -9.64%
    Wide Bands Range Expansion -9.64%
    Oversold Stochastic Weakness -9.64%
    Older End-of-Day Signals for MIRA ...

       Recent Intraday Alerts

    Alert Time
    200 DMA Support about 18 hours ago
    Down 5% about 18 hours ago
    Down 3% about 18 hours ago
    Fell Below 50 DMA about 18 hours ago
    Fell Below Previous Day's Low about 18 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MIRA Chart by TradingView
    Basic chart:

    Profile

    MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog for treating anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - General
    Keywords: Cannabis Euphoriants Chronic Pain Entheogens Cannabinoid Antiemetics Ajulemic Acid

    Is MIRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 MIRA Continues Solid Financial Management
    Oct 29 MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials
    Oct 28 MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
    Oct 28 MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
    Oct 27 Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024
    Oct 21 MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
    Oct 21 MIRA Continues to Post Outstanding Test Results
    Sep 27 MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
    Sep 18 MIRA Makes Impressive Progress
    Sep 18 MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
    See more MIRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.01
    52 Week Low 0.51
    Average Volume 1,698,947
    200-Day Moving Average 1.23
    50-Day Moving Average 1.34
    20-Day Moving Average 1.63
    10-Day Moving Average 1.52
    Average True Range 0.21
    RSI (14) 40.48
    ADX 23.78
    +DI 19.08
    -DI 25.74
    Chandelier Exit (Long, 3 ATRs) 1.93
    Chandelier Exit (Short, 3 ATRs) 1.67
    Upper Bollinger Bands 2.18
    Lower Bollinger Band 1.09
    Percent B (%b) 0.16
    BandWidth 66.61
    MACD Line 0.01
    MACD Signal Line 0.07
    MACD Histogram -0.06
    Fundamentals Value
    Market Cap 18.7 Million
    Num Shares 14.8 Million
    EPS -0.51
    Price-to-Earnings (P/E) Ratio -2.48
    Price-to-Sales 0.00
    Price-to-Book 1.93
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.69
    Resistance 3 (R3) 1.69 1.55 1.62
    Resistance 2 (R2) 1.55 1.44 1.55 1.59
    Resistance 1 (R1) 1.41 1.38 1.34 1.41 1.57
    Pivot Point 1.27 1.27 1.23 1.27 1.27
    Support 1 (S1) 1.13 1.16 1.06 1.13 0.96
    Support 2 (S2) 0.99 1.10 0.99 0.94
    Support 3 (S3) 0.85 0.99 0.92
    Support 4 (S4) 0.85